Published online Jan 18, 2023.
https://doi.org/10.12997/jla.2023.12.1.87
Journal of Lipid and Atherosclerosis (JLA) was indexed in PubMed Central in 2019 and in Scopus in 2020. JLA has developed to publish more than 25 high-qualified review, original article, brief report, letter to the editor and editorial in 2021. Authors from 8 countries published reviews and original articles in JLA.
The number of total citations continuously increased. An estimated impact factor in Web of Science achieved a rising Journal Citation Reports (JCR) impact factor of 3.71(estimated value at December 1st, 2022), which corresponds to Journal Impact Factor Quartile 2 (Q2) in Biochemical Research Methods category, Quartile 3 (Q3) in Endocrinology & Metabolism category and Q3 in Peripheral Vascular Disease category (values are compared with JCR2022). In addition, the CiteScore Tracker 2022 (last updated on December 6th, 2022, available from: https://www.scopus.com/sourceid/21101032315) calculated by Scopus was 4.3 (342 citations to date/145 documents 2018 to date). This is a substantial increase compared with the 1.9 from the CiteScore Tracker 2021, in which the journal ranked 38th percentile in Internal Medicine category, 36th percentile in Cardiology and Cardiovascular Medicine category and 29th percentile in Endocrinology, Diabetes and Metabolism category. This is an unprecedented pace of development.
Funding:None.
Conflict to Interest:Hyun Kang has been a statistical editor from 2020 to 2021 and Editor-in-Chief since 2023 of the Journal of Lipid and Atherosclerosis. However, he was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.
